Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cryptosporidium immune whey protein concentrate, also known as BACI (bovine anti-Cryptosporidium immunoglobulin), is a bovine-derived biologic therapy developed by Univax Biologics for the treatment of cryptosporidiosis, specifically in patients with AIDS. It is produced from the whey of hyperimmune colostrum collected from cows immunized with *Cryptosporidium parvum*. The product contains high titers of specific IgG antibodies intended to provide passive immunity within the gastrointestinal tract, neutralizing the parasite and reducing the severity of diarrhea. Clinical development reached Phase 2 trials in the 1990s but was ultimately discontinued following mixed efficacy results and corporate restructuring.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cryptosporidium immune whey protein concentrate.